ClinicalTrials.gg
CompletedNCT07024797Updated Dec 31, 2025

Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants

A Phase 1 interventional study of ABBV-932 and Placebo for ABBV-932 in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will assess the adverse events, tolerability, and how oral doses of ABBV-932 moves through the body in healthy adult Chinese participants.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ABBV-932
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥ 18.0 to ≤ 27.9 kg/m\^2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy, any cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, unexplained syncope, or any uncontrolled medical illness.
  • History of suicidal ideation within one year prior to study treatment administration as evidenced by answering "yes" to questions 4 or 5 on the suicidal ideation portion of the C-SSRS completed at Screening, or any history of suicide attempts as evidenced by answering "yes" to any suicidal behavior question (except a "yes" to the "Has subject engaged in non-suicidal self-injurious behavior" question) within the last 2 years.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    ABBV-932 or Placebo Part A

    Participants will receive oral ABBV-932 or placebo once daily (QD) for 14 days.

    Drug: ABBV-932 · Drug: Placebo for ABBV-932

  • Experimental
    ABBV-932 or Placebo Part B

    Participants will receive oral ABBV-932 or placebo QD for 14 days.

    Drug: ABBV-932 · Drug: Placebo for ABBV-932

  • Experimental
    ABBV-932 or Placebo Part C

    Participants will receive oral ABBV-932 or placebo QD 42 days.

    Drug: ABBV-932 · Drug: Placebo for ABBV-932

Interventions

  • Oral Capsule

  • DrugPlacebo for ABBV-932

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of ABBV-932

    Cmax of ABBV-932

    Time frame: Up to approximately 43 days

  2. Time to Cmax (Tmax) of ABBV-932

    Tmax of ABBV-932

    Time frame: Up to approximately 43 days

  3. Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-932

    Ctrough of ABBV-932

    Time frame: Up to approximately 43 days

  4. Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of Desmethyl Cariprazine ABBV-932

    AUCtau of ABBV-932

    Time frame: Up to approximately 43 days

  5. Maximum Plasma Concentration (Cmax) of DCAR

    Cmax of DCAR

    Time frame: Up to approximately 43 days

  6. Time to Cmax (Tmax) of DCAR

    Tmax of DCAR

    Time frame: Up to approximately 43 days

  7. Observed plasma concentration at the end of a dosing interval (Ctrough) of DCAR

    Ctrough of DCAR

    Time frame: Up to approximately 43 days

  8. Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of Desmethyl Cariprazine (DCAR)

    AUCtau of DCAR

    Time frame: Up to approximately 43 days

  9. Maximum Plasma Concentration (Cmax) of Didesmethyl-Cariprazine (DDCAR)

    Cmax of DDCAR

    Time frame: Up to approximately 43 days

  10. Time to Cmax (Tmax) of DDCAR

    Tmax of DDCAR

    Time frame: Up to approximately 43 days

  11. Observed plasma concentration at the end of a dosing interval (Ctrough) of DDCAR

    Ctrough of DDCAR

    Time frame: Up to approximately 43 days

  12. Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of DDCAR

    AUCtau of DDCAR

    Time frame: Up to approximately 43 days

  13. Number of Participants Experiencing Adverse Events

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 75 days

07

Study locations

1 site
  • Shanghai Mental Health Center /ID# 273427
    Shanghai, Shanghai Municipality 200030, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Dec 2025, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2025
First posted
Jun 17, 2025
StartActual
Aug 21, 2025
Primary completionActual
Dec 8, 2025
CompletionActual
Dec 8, 2025
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07024797
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Aug 21, 2025
Primary completion
Dec 8, 2025
Completion
Dec 8, 2025
Last update
Dec 31, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-932

Start the discussion